NOVARTIS AG-SPONSORED ADR (NVS)
US66987V1098 - ADR
ChartMill assigns a Buy % Consensus number of 71% to NVS. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 121.81. This target is 17.3% above the current price.
NVS was analyzed by 30 analysts. The buy percentage consensus is at 71. So analysts seem to be have mildly positive about NVS.
In the previous month the buy percentage consensus was at a similar level.
NVS was analyzed by 30 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-11-19 | Erste Group | Downgrade | Buy -> Hold |
| 2024-10-30 | BMO Capital | Maintains | Market Perform -> Market Perform |
| 2024-09-11 | B of A Securities | Downgrade | Buy -> Neutral |
| 2024-09-05 | Goldman Sachs | Downgrade | Buy -> Neutral |
| 2024-09-03 | Jefferies | Downgrade | Buy -> Hold |
| 2024-07-02 | Jefferies | Maintains | Buy -> Buy |
| 2024-04-24 | BMO Capital | Maintains | Market Perform -> Market Perform |
| 2024-02-23 | BMO Capital | Initiate | Market Perform |
| 2024-01-23 | Morgan Stanley | Initiate | Equal-Weight |
| 2023-09-25 | Morgan Stanley | Upgrade | Underweight -> Equal-Weight |
| 2022-05-09 | Wolfe Research | Downgrade | Outperform -> Peer Perform |
| 2021-12-06 | Exane BNP Paribas | Downgrade | Outperform -> Neutral |
| 2021-12-03 | Bryan Garnier | Downgrade | Buy -> Neutral |
| 2021-09-20 | Deutsche Bank | Downgrade | Hold -> Sell |